CareLit · DOI-Nachweis · Klinische Pädiatrie
Long-term infusion of anti-GD2 antibody ch14.18/CHO is active and less toxic in high-risk neuroblastoma patients
DOI 10.1055/s-0033-1343656
Bibliografische Angaben
Nachweis in CareLit
Autor:innenD Brackrock, S Endres, L Pill, S Kietz, I Müller, U Grunwald, N Siebert, HN Lode
ZeitschriftKlinische Pädiatrie
Ausgabe05/2013
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Purpose: GD2 is highly expressed in neuroblastoma (NB) and specifically recognized by monoclonal antibody ch14.18/CHO (Ab). Immunotherapy with bolus infusion of ch14.18 effectively prolonged survival. We piloted a treatment with continuous infusion of ch14.18 in combination with IL2 aiming at a reduction of toxicity and maintaining immune modulation. Methods and Materials: The pain level was analyzed by validated pa…
Zitieren
Zitierempfehlung
D Brackrock, S Endres, L Pill, S Kietz, I Müller, U Grunwald, N Siebert, HN Lode (2013) Long-term infusion of anti-GD2 antibody ch14.18/CHO is active and less toxic in high-risk neuroblastoma patients. Klinische Pädiatrie (05). https://doi.org/10.1055/s-0033-1343656
Mit CareLit weiterarbeiten